EFSA Confirms Bioavailability of Magnesium Citrate Malate for Bone and Muscle Claims

EFSA has published a positive scientific opinion regarding the safety and bioavailability of Magnesium Citrate Malate as a source of magnesium in food supplements. This ruling allows formulators to integrate this specific chelate into high-potency formulations while maintaining compliance with Regulation EC 1924/2006 for skeletal and muscular health claims.

Formulation Benefits and Density Gains

If you are launching a magnesium complex in Q4, switch to Magnesium Citrate Malate to resolve volume issues in size 00 capsules. Standard Magnesium Citrate often requires bulky fillers or multiple capsules to hit the 56mg elemental magnesium target per serving. The hybrid molecule offers better packing density.

• Elemental magnesium content averages 12 to 15 percent depending on the specific molar ratio
• Higher solubility in water compared to magnesium oxide or carbonate
• Reduced GI distress reports in pilot consumer groups compared to magnesium sulfate
• Current spot price sits at 18.50 EUR per kg for EU-stocked material

Procurement and Regulatory Strategy

Procurement managers should lock in contracts now as demand for this specific salt will rise following the EFSA clearance. The opinion clarifies that this form is equivalent to other approved salts like magnesium bisglycinate in terms of safety profiles at doses up to 250mg of elemental magnesium per day.

Check your specification sheets for heavy metal limits. The new ruling emphasizes that lead levels must remain below 3.0 mg per kg. Brands sourcing from non-EU manufacturers must demand batch-specific ICP-MS reports to avoid detention at the border. Transitioning your bone health SKUs to this form by January 2027 will likely reduce your cost-per-serving by 8 percent compared to pure bisglycinate blends.